<table id="_RefID0F7DCE4BFDC7490A81DA7D058F357213" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1: Select Mean (±S.D.) Metformin Pharmacokinetic Parameters Following Single or Multiple Oral Doses of Metformin Hydrochloride Tablets </caption>
<col width="44%"></col>
<col width="14%"></col>
<col width="14%"></col>
<col width="29%"></col>
<thead>
<tr>
<th align="center" stylecode="Botrule Lrule Toprule " valign="top">
<content stylecode="bold">Subject Groups: Metformin Hydrochloride</content>
<br/>
<content stylecode="bold">Tablets dose<sup>a</sup> (number of subjects)  </content>
</th>
<th align="center" stylecode="Botrule Lrule Toprule " valign="top">
<content stylecode="bold">C<sub>max</sub>
<sup>b</sup>
</content>
<br/>
<content stylecode="bold">(µg/mL)</content>
</th>
<th align="center" stylecode="Botrule Lrule Toprule " valign="top">
<content stylecode="bold">T<sub>max</sub>
<sup>c</sup>
</content>
<br/>
<content stylecode="bold">(hrs) </content>
</th>
<th align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<content stylecode="bold">Renal Clearance (mL/min)  </content>
</th>
</tr>
</thead>
<tbody>
<tr>
<td stylecode="Lrule Toprule Botrule ">
<paragraph>
<content stylecode="bold">Healthy, nondiabetic adults:</content>
<br/>500 mg single dose (24)<br/>850 mg single dose (74) <sup>d</sup>
<br/>850 mg three times daily for 19 doses<sup>e</sup> (9)  </paragraph>
</td>
<td align="center" stylecode="Lrule Toprule Botrule ">
<paragraph>1.03 (±0.33)<br/>1.60 (±0.38)<br/>2.01 (±0.42) </paragraph>
</td>
<td align="center" stylecode="Lrule Toprule Botrule ">
<paragraph>2.75 (±0.8)<br/>2.64 (±0.8)<br/>1.79 (±0.9)</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>600 (±132)<br/>552 (±139)<br/>642 (±173) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>
<content stylecode="bold">Adults with type 2 diabetes:</content>
<br/>850 mg single dose (23)<br/>850 mg three times daily for 19 doses<sup>e</sup> (9)<br/>
</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule ">
<paragraph>1.48 (±0.5)<br/>1.90 (±0.62)</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule ">
<paragraph>3.32 (±1.08)<br/>2.01 (±1.22)</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>491 (±138)<br/>550 (±160)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>
<content stylecode="bold">Elderly<sup>f</sup>, healthy nondiabetic adults:</content>
<br/>850 mg single dose (12)<br/>
</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule ">
<paragraph>2.45 (±0.70)</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule ">
<paragraph>2.71 (±1.05)</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>412 (±98)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>
<content stylecode="bold">Renal-impaired adults:</content>
<br/>
<content stylecode="bold">850 mg single dose</content>
<br/>
<content stylecode="bold">Mild </content>(CL<sub>cr</sub>
<sup>g</sup> 61-90 mL/min) (5)<br/>
<content stylecode="bold">Moderate </content>(CL<sub>cr</sub> 31-60 mL/min) (4)<br/>
<content stylecode="bold">Severe </content>(CL<sub>cr</sub> 10-30 mL/min) (6)<br/>
</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule ">
<paragraph>1.86 (±0.52)<br/>4.12 (±1.83)<br/>3.93 (±0.92)</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule ">
<paragraph>3.20 (±0.45)<br/>3.75 (±0.50)<br/>4.01 (±1.10)</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule ">
<paragraph>384 (±122)<br/>108 (±57)<br/>130 (±90)</paragraph>
</td>
</tr>
<tr>
<td colspan="4" stylecode="Rrule Botrule Lrule ">
<paragraph>
<sup>a</sup>  All doses given fasting except the first 18 doses of the multiple dose studies</paragraph>
<paragraph>
<sup>b</sup> Peak plasma concentration </paragraph>
<paragraph>
<sup>c</sup> Time to peak plasma concentration </paragraph>
<paragraph>
<sup>d</sup> Combined results (average means) of five studies: mean age 32 years (range 23-59 years)</paragraph>
<paragraph>
<sup>e</sup> Kinetic study done following dose 19, given fasting</paragraph>
<paragraph>
<sup>f</sup>  Elderly subjects, mean age 71 years (range 65-81 years)</paragraph>
<paragraph>
<sup>g</sup>  CL<sub>cr</sub> = creatinine clearance normalized to body surface area of 1.73 m<sup>2</sup>
</paragraph>
</td>
</tr>
</tbody>
</table>